

1 **PUM1 represses CDKN1B translation and contributes to prostate cancer**
2 **progression**

3

4 **Running title: Translational regulation of prostate cancer**

5

6 Xin Li^{1#}, Jian Yang^{1,2#}, Xia Chen¹, Dandan Cao¹ and Eugene Yujun Xu^{1,3*}

7

8 ¹State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing,
9 211166, China

10 ²Urology Department, The Second Affiliated Hospital of Nanjing Medical University,
11 Nanjing, 211166, China

12 ³Department of Neurology, Feinberg School of Medicine, Northwestern University

13 # Equal contribution

14 Contact: Dr. Eugene Y Xu e-xu@northwestern.edu

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

31 **Abstract**

32 Posttranscriptional regulation of cancer gene expression programs plays a vital role
33 in carcinogenesis; identifying the critical regulators of tumorigenesis and their
34 molecular targets may provide novel strategies for cancer diagnosis and therapeutics.
35 Highly conserved RNA binding protein PUM1 regulates mouse growth and cell
36 proliferation, propelling us to examine its role in cancer. We found human *PUM1* is
37 highly expressed in a diverse group of cancer, including prostate cancer; enhanced
38 PUM1 expression is also correlated with reduced survival among prostate cancer
39 patients. Detailed expression analysis in twenty prostate cancer tissues showed
40 enhanced expression of *PUM1* at mRNA and protein levels. Knockdown of *PUM1*
41 reduced prostate cancer cell proliferation and colony formation, and subcutaneous
42 injection of *PUM1* knockdown cells led to reduced tumor size. Downregulation of
43 PUM1 in prostate cancer cells consistently elevated CDKN1B protein expression
44 through increased translation but did not impact its mRNA level, while overexpression
45 of PUM1 reduced CDKN1B protein level. Our finding established a critical role of
46 PUM1 mediated translational control, particularly the PUM1-CDKN1B axis, in
47 prostate cancer cell growth and tumorigenesis. We proposed that PUM1-CDKN1B
48 regulatory axis may represent a novel mechanism for the loss of CDKN1B protein
49 expression in diverse cancers and could be potential targets for therapeutics
50 development.

51

52 **Keywords:** PUM1, Prostate cancer, Posttranscriptional regulation, CDKN1B

53

54

55

56

57

58

59

60

61 **Introduction**

62 Prostate cancer is the most common cancer and one of the leading causes of cancer
63 death in men. Overexpression of RBPs (RNA Binding Proteins) in prostate cancer (PCa)
64 supports that posttranscriptional control plays a vital role in prostate carcinogenesis [1].
65 Only a few posttranscriptional regulators have been identified, and even fewer are
66 mechanistically understood [2, 3].

67 Human homologs of a significant proportion of mouse growth genes are also
68 essential for tumorigenesis, either as oncogenes or tumor suppressors. Many of the
69 growth regulators or tumorigenesis regulators are transcriptional regulators [4], the role
70 of posttranscriptional regulation has begun to be appreciated [2]. Characterization of
71 conserved RNA binding proteins in mammalian growth and tumorigenesis could help
72 identify novel regulators and pathways important for cancer diagnosis and therapeutics
73 development.

74 One of the highly conserved eukaryotic RNA-binding proteins, the PUF family
75 (Pumilio and FBF), functions by binding to Pumilio Binding Elements (PBE) on the
76 3'UTR of their target mRNAs and play critical roles in cell fate decision and
77 differentiation [2, 5-7]. Recent genetic studies on members of the mammalian PUF family,
78 *Pum1* and *Pum2*, uncovered roles of PUM-mediated posttranscriptional regulation in
79 growth, reproductive and neuronal development as well as diseases [8-16]. *Pum* mutant
80 mice have reduced body weight and size, resulting from enhanced cell cycle inhibitor
81 expression, *Cdkn1b*, and reduced cell proliferation, raising the possibility that PUM-
82 CDKN1B regulatory pathway may also be important in human growth and cell
83 proliferation [15].

84 The p27Kip1 (*Cdkn1b*) gene is a member of the Cip/Kip family of cyclin-dependent
85 kinase (CDK) inhibitors that function to negatively control cell cycle progression by
86 association with cyclin-dependent kinase 2 (CDK2) and cyclin E complexes to inhibit
87 the transition from G1 to S phase [17]. Previous work has demonstrated that *CDKN1B*
88 is a haploinsufficient tumor suppressor whose protein level has to be fine-tuned for its
89 optimal function, and CDKN1B protein level may have prognostic and therapeutic
90 implications [17-19]. While impaired synthesis, accelerated degradation, and

91 mislocalization of CDKN1B have been studied ^[19], regulation of CDKN1B protein
92 expression via translation in cancer has not been explored, and whether there exist key
93 translational regulators remained unknown. We propose that *Pum1* may exert control
94 on human cell growth, in particular cancer cell growth, by repressing *Cdkn1b*
95 expression ^[15].

96 Association of PUM with cancer cell growth has been suggested from studies on
97 cancer cell lines ^[20-22], examination of PUM expression in human tumorigenesis and
98 characterization of PUM mediated translation control directly in human cancer cells
99 and the tumor is needed to reveal the extent and mechanism of PUM-mediated
100 regulation during human tumorigenesis. Here, we report increased expression of PUM1
101 in various cancers from an extensive collection of human cancer datasets and twenty
102 prostate tumor samples we collected from the clinic. We uncovered a role of PUM1-
103 mediated translational repression of CDKN1B in prostate cancer cell proliferation and
104 tumor formation. Our data underscore the importance of the PUM1-CDKN1B
105 regulatory axis in human carcinogenesis and its potential for developing novel
106 strategies in cancer diagnosis and therapeutics.

107 **Material and Methods**

108 **Patients and Tissue Samples**

109 All human studies were approved by the Institutional Ethics Committee of Nanjing
110 Medical University and performed after obtaining written informed consent. Twenty
111 patients (mean age 70.5 years, range 61-76 years) underwent radical prostatectomy for
112 prostate adenocarcinoma at the Second Affiliated Hospital of Nanjing Medical
113 University. A summary of clinic and pathology parameters for the study cohort is
114 included in Supplemental Table II. For prostate cancer samples, the predominant tumor
115 nodule and matched normal tissue were identified by histopathologists on fresh-frozen
116 sections. Only foci with >80% purity of cancer cells were collected. Each prostate
117 cancer and matched normal tissue were cut into three pieces. Among them, two parts
118 were immediately frozen in liquid nitrogen and stored at -80°C for later protein and
119 RNA extraction, one piece of tissue was fixed in 10% neutral buffered formalin for 24
120 hours. The procedure for this research conforms to the provisions of the Declaration of

121 Helsinki.

122 **Immunohistochemistry**

123 The histologic specimens were fixed in 10% formalin and routinely processed for
124 paraffin embedding. Histologic sections, 5-mm thick, were stained with hematoxylin-
125 eosin and reviewed by two pathologists to define the prostate cancer and matched
126 normal tissues. Immunohistochemistry was performed on tumor paraffin sections after
127 antigen retrieval using antibodies directed against PUM1 (Abcam, ab92545), according
128 to the protocol described previously [15]. Specificity of PUM1 antibody has been
129 confirmed using tissues from *Pum1* knockout mice [15].

130 **Western Blot**

131 Total protein was collected using the RIPA (Beyotime, P0013B) and protease
132 inhibitor cocktail (Roche, Basel). Standard Western blotting procedure [15] was followed
133 with PVDF membrane (Bio-Rad) used for protein transfer. Detection of HRP
134 conjugated secondary antibody was performed with ECL (PerkinElmer). The
135 antibodies used were as follows: Rabbit anti-PUM1 (Abcam, ab92545), mouse anti-
136 ACTIN (SIGMA, A1978), rabbit anti-CDKN1B (CST, #2552P), mouse anti-GAPDH
137 (Protein tech, 60004-1-Ig), Mouse anti-Tubulin (Santa Cruz, sc-8035). The band
138 intensity of specific proteins was quantified after normalization with that of β -ACTIN
139 or GAPDH.

140 **RNA Extraction and RT-PCR Analysis**

141 RNA was extracted by Trizol from tissues or cells stored at -80°C and reverse
142 transcribed for amplification of *PUM1* cDNA. RT-qPCR analysis was performed using
143 gene-specific sets of primers (Supplementary Table SI). The gene expression analysis
144 was detected by ABI BioSystem StepOne plus. The gene expression level was
145 quantified relative to the expression of β -ACTIN, and the specificity of PCR products
146 was confirmed by melting curve analysis. Each reaction filled up to an end volume of
147 20 μ L containing two μ l template cDNA, ten μ l SYBR Premix Ex Taq buffer (TaKaRa,
148 RR820A), 0.4 μ l ROX Reference Dye, eight pmol of each primer, and six μ l ddH₂O
149 and was carried out in a standard 96-well plate. The cycling conditions consisted of an
150 initial incubation at 95 °C for 3 min, followed by 45 cycles of 94°C for 30 s, 60°C for

151 30 s, and 72°C for 30 s. A final incubation terminated the reaction at 95°C for 15 s,
152 60°C for 30 s, and 95°C for 15 s. The expression level was calculated by the $2^{-\Delta\Delta Ct}$
153 method to compare the relative expression.

154 **Luciferase reporter assay**

155 *CDKN1B* 3'UTR was subcloned into psiCHECK-2 vector (Promega) using XhoI and
156 PmeI restriction enzymes (New England Biolabs). Wild-type PBE sequences 5'-
157 TGTATATA-3' was mutant to 5'-acaATATA-3' as previous report ^[12]. Cells were co-
158 transfected with pCMV6-hPUM1 and luciferase reporter plasmids, containing
159 fragments or full-length 3'UTRs. After 48 hours, cells were washed with PBS and lysed
160 in Passive Lysis Buffer (Promega, Chroma-Glo™ Luciferase Assay System). 20μl of
161 each lysate was analyzed using the Dual-Luciferase Reporter Assay System (Promega,
162 Chroma-Glo™ Luciferase Assay System) in a 96 Microplate luminometer (BioTek,
163 USA).

164 **Sucrose gradient polysome fractionation**

165 2×10^7 DU145 cells were collected, washed with PBS, and homogenized in 0.5mL of
166 MCB buffer. The lysate was centrifuged at 1300g at 4°C for 10 min. The supernatant
167 was applied onto the top of a 15–55% (W/W) linear sucrose gradient made by the
168 Density Gradient Fractionation System (Teledyne ISCO Inc.). The gradient was
169 centrifuged at 150000g for three hours (Beckman, USA). Fractions were collected and
170 used for RNA extraction and analysis.

171 **Colony formation**

172 DU145 cells were generated by hPUM1 shRNA or scramble control lentiviral
173 infection followed by puromycin selection. Cells were then trypsinized and counted by
174 a hemocytometer. In total, 1×10^4 *PUM1* knockdown or overexpressing DU-145 cells
175 were seeded in complete growth media and allowed to grow for 14–21 days until visible
176 colonies formed. Colonies were stained with 0.25 % crystal violet in ddH₂O, washed
177 with PBS twice, and air-dried.

178 **Xenograft model in vivo**

179 Six-week-old male nude mice (BALB/c, Charles River) were used for the xenograft
180 experiments. Cancer cells were trypsinized and harvested in PBS, then a total volume

181 of 0.1 ml PBS was subcutaneously injected into the inguinal regions. DU-145 cells
182 (5×10^5) transduced with sh-PUM1KD1 or Sh-Con were subcutaneously injected into
183 the left and right inguinal regions of nude mice, respectively and the nude mice were
184 monitored for 49 days. Tumor sizes were measured twice a week, starting at two weeks
185 after cell injection using Vernier caliper. The animal study protocol was reviewed and
186 approved by the institutional animal care and use committee of Nanjing Medical
187 University.

188 **Statistical analysis**

189 All experiments were repeated at least three times. Statistical significance between
190 two groups of data was evaluated by Student's t-test (two-tailed) comparison using
191 GraphPad Prism software 7.

192 **Results**

193 **PUM1 expression is upregulated in various cancers, and overexpression of PUM1** 194 **is associated with poor prognosis in prostate cancer patients.**

195 To determine whether PUM1 has a role in tumorigenesis, we first examined PUM1
196 expression in the TCGA database and found that PUM1 is widely expressed in diverse
197 cancers, including prostate cancer (Fig. 1A). Given the reported correlation of loss of
198 CDKN1B expression with prostate cancer survival [18], we hence investigated the role
199 of PUM1 expression in prostate cancer. By focusing on 101 prostate samples from the
200 TCGA database [23], we found that *PUM1* mRNA was significantly higher in prostate
201 carcinoma than that in benign tissues ($P < 0.05$) (Fig. 1B). Compared with the normal
202 prostate gland, a substantially higher level of PUM1 protein in prostate carcinoma was
203 observed by immune-histochemical staining assays (Fig. 1C). Furthermore, the Kaplan-
204 Meier curves indicated a significant correlation of PUM1 protein upregulation with
205 poor patient survival (Fig. 1D). Hence, our analysis of TCGA cohorts suggested that
206 PUM1 upregulation is associated with tumorigenicity, particularly prostate cancer, and
207 poor outcomes in PCa patients.

208 To further verify the correlation between PUM1 expression and PCa, we collected
209 and analyzed PCa specimens from 20 prostate carcinoma patients in the clinic
210 (Supplemental Table II). RT-qPCR from total RNA obtained from PCa tissue and

211 matched normal tissue confirmed the upregulation of *PUM1* at the mRNA level in most
212 of the patients examined (Fig. 1E). Western blot analysis was performed on extracts
213 obtained from the neoplastic tissue and from the gland's contralateral part. We found
214 that PUM1 protein was consistently upregulated in the neoplastic tissues, mostly basal
215 cells (Fig. 1F and 1G). PUM1 protein was also detected in two types of prostate cancer
216 cells (DU145 and PC3) (Fig. 1F). To further determine the localization of PUM1 protein
217 in the prostate cancer tissue, we performed immunohistochemistry analysis on tissues
218 of the same group of patients. PUM1 was expressed at low levels in the epithelial cells
219 of matched normal prostate glands. By contrast, all epithelial cells of neoplastic glands
220 were strongly positive for PUM1 (Fig. 1H), which confirmed that expression of PUM1
221 is indeed elevated in the neoplastic phenotype of prostate epithelial cells.

222 **Downregulation of PUM1 in prostate cancer cells decreased proliferation and**
223 **induced apoptosis.**

224 To understand the role of PUM1 in prostate carcinogenesis, we first interrogated the
225 role of PUM1 in prostate cancer cell lines. We chose two commonly used prostate
226 cancer cell lines representing different metastatic potentials of prostatic
227 adenocarcinoma for our experiments, with PC3 from grade IV adenocarcinoma with
228 high metastatic potential and DU145 from prostate carcinoma with moderated
229 metastatic potential. Two *PUM1* small hairpin knockdown shRNAs were designed
230 against different parts of the *PUM1* sequence and transfected into DU145 and PC3 cells.
231 We found that *PUM1* mRNAs were significantly reduced in DU145 and PC3 cells
232 transduced with the *PUM1* knockdown shRNA, confirming specific and efficient
233 repression of PUM1 (Fig. 2A). Western blot analysis confirmed the reduction of PUM1
234 protein in both DU145 and PC3 cells containing either knockdown construct (Fig. 2B).
235 Consistent with the previous report in mouse cells ^[12], CCK8 assays indicated that the
236 downregulation of *PUM1* causes a decrease in the proliferation rate of DU145 cells
237 (Fig. 2C). Growth inhibition by *PUM1* knockdown was also confirmed in PC3 cells
238 (Fig. 2D). Annexin V/propidium iodide (PI) assay showed the population of apoptotic
239 cells increased 1.41- and 1.35-fold in DU145, and 2.14- and 2.26-fold in PC3 when
240 PUM1 was knocked down in these cells (Fig. 2E and 2F). Moreover, cleaved Caspase-

241 3 and cleaved Caspase-9 were also increased in both cell lines upon *PUM1* knockdown
242 (Fig. 2G). The reduced cell growth was due to inhibition of G1/S transition: *PUM1*
243 knockdown significantly reduced DU145 cells in the S phase as assessed by
244 incorporation of Edu (Fig. 2H) and DNA content (Fig. 2I). Together with our data
245 demonstrated that an elevated PUM1 level is critical for the increased growth rate of
246 prostate cancer cells.

247 **Overexpression of *PUM1* promotes prostate cancer cell proliferation and colony** 248 **formation**

249 Since PUM1 level is positively correlated with prostate cancer cells' proliferation
250 rate, we asked if overexpression of *PUM1* could further promote the proliferation of
251 prostate cancer cells. The expression levels of PUM1 in DU145 cells were manipulated
252 by transfection of *PUM1* knockdown construct and/or retroviral vector for *PUM1* (Fig.
253 3A). *PUM1* overexpression significantly increased the growth rate of DU145 (Fig. 3B).
254 When PUM1 level was restored by retrovirus vector carrying *PUM1* gene, the growth
255 rate of *PUM1*-knockdown cells became comparable to that of control cells (shCTL +
256 Empty retroviral vector), supporting *PUM1* knockdown being responsible for reduced
257 proliferation (Fig. 3B).

258 We next asked the role of PUM1 in cell transformation by measuring the effect of
259 PUM1 expression levels on the anchorage-independent growth of DU145 cells in soft
260 agar assay. The total number of colonies was significantly reduced with *PUM1*-
261 knockdown, while overexpression of *PUM1* led to a substantially higher number of
262 colonies (Fig. 3C and 3D). Overexpressing *PUM1* in the cells with *PUM1*-knockdown
263 rescued the ability of DU145 cells to form a comparable number of colonies, consistent
264 with its rescue effect in cell proliferation. The positive correlation between PUM1
265 expression level and anchorage-independent growth further supports our hypothesis
266 that PUM1 plays a critical role in prostate carcinogenesis.

267 **Reduced PUM1 expression represses prostate tumorigenesis *in vivo***

268 To test our hypothesis that PUM1 is essential for the growth of prostate cancer cells,
269 we examined the effect of *PUM1*-knockdown on the tumorigenic capacity of DU145
270 cells in nude mice. DU145 cells transduced with an shRNA for *PUM1* (sh-PUM1) or a

271 control shRNA (ShCTL) were injected into the left and right inguinal regions of the
272 same nude mice (Fig. 4A and 4B). By both tumor weight and volumes, knockdown of
273 *PUM1* significantly reduced the tumor growth (Fig. 4C and 4G). These results confirm
274 the oncogenic activity of *PUM1* in vivo and suggest that *PUM1* may represent a
275 potential target of therapeutic treatment for prostate cancer. Further exploration and
276 investigation into PUM1's regulatory mechanism could provide insight into such an
277 approach's feasibility.

278 **PUM1 represses the translation of tumor suppressor CDKN1B via binding to its** 279 **PBE in prostate cancer cell**

280 Genetic analyses established that *Cdkn1b* is a tumor suppressor in the prostate
281 controlling prostatic epithelium growth [19]. According to TCGA data, *CDKN1B*
282 expression was observed to be downregulated in prostate cancer compared to normal
283 tissues (Fig. 5A). Base on previous reports, we wondered whether PUM1 is involved
284 in tumorigenesis via regulating CDKN1B expression. We then evaluated the correlation
285 between PUM1 and CDKN1B gene expression with the TCGA-based GEPIA tool, and
286 the plots showed that PUM1 and CDKN1B expression is correlated in PCa with
287 Pearson correlation coefficient being 0.63 (Fig. 5B). RT-qPCR showed *CDKN1B*
288 mRNA was unaffected in both DU145 and PC3 cells with *PUM1*-knockdown (Fig. 5C).

289 To determine the molecular mechanism by which PUM1 contributed to cell
290 proliferation and progression of prostate cancer, we analyzed the protein expression
291 change of cell cycle regulators after inhibiting PUM1 expression. While other target
292 cell cycle regulators exhibited variable changes or no changes in PUM1 knockdown
293 cells, the protein expression of CDKN1B consistently increased upon knockdown of
294 *PUM1* in both PC3 and DU145 cell lines, supporting CDKN1B as a major cell cycle
295 downstream target of PUM1 protein (Fig. 5D and 5E).

296 To further determine if PUM1-mediated repression of CDKN1B is specific to
297 androgen-insensitive DU145 and PC3 cell lines or general to all different types of
298 prostate cancer cells, we chose LNCap cell line, which differ from DU145 and PC3 in
299 that LNCap not only is from prostate carcinoma with low metastatic potential but also
300 expresses androgen receptor and is androgen-sensitive. Knockdown of *PUM1* led to a

301 significant reduction of PUM1 expression. The examination of cell cycle regulators
302 showed a various degree of protein expression changes, CDKN1B exhibited the highest
303 increase in protein expression, supporting PUM1-mediated repression of CDKN1B
304 may be a general mechanism among prostate cancer cells (Fig. 5F). CCND1 protein
305 was slightly increased while p21 protein is slightly decreased (Fig. 5F). These results
306 suggested that PUM1-CDKN1B axis may represent a major regulatory axis in both AR-
307 positive and -negative PC cells.

308 Given that CDKN1B protein but not RNA increased in the *PUM1* knockdown cells,
309 we performed RNA immunoprecipitation (RIP) and dual luciferase assay to test if
310 PUM1 directly regulates the translation of CDKN1B via binding to the two PBEs of its
311 3'UTR in prostate cancer cells. In the RNA immunoprecipitation experiment, we found
312 that the pull-down fraction of PUM1 protein was significantly enriched with *CDKN1B*
313 mRNAs, consistent with direct binding of PUM1 (Fig. 6A and 6B). Thus, *CDKN1B*
314 mRNA is associated with PUM1 protein in DU145 and PC3 cells. Next, we constructed
315 a luciferase reporter construct containing wildtype 3'UTR or mutant 3'UTR of
316 *CDKN1B* mRNA with both PBE sites mutated (Fig. 6C). While PUM1 overexpression
317 repressed expression of the reporter expression with wildtype *CDKN1B* 3'UTR,
318 mutations on PBEs negated the repressive effect of PUM1 on the reporter (Fig. 6C).
319 These results supported that PBE sites on the 3'UTR of *CDKN1B* are critical for PUM1
320 mediated translational repression in prostate cancer cells.

321 To test if PUM1 regulates the translation CDKN1B expression in prostate cancer
322 cells, we performed a polysome fractionation experiment in DU145 cells transfected
323 with or without a *PUM1* knockdown construct. *PUM1* knockdown significantly
324 enriched CDKN1B mRNA in actively translating fraction, polysome fraction (Fig. 6D
325 and 6E), indicating CDKN1B protein translation is promoted by *PUM1* knockdown.
326 Together, these results supported our hypothesis that increased PUM1 expression may
327 contribute to the growth of prostate cancer cells via translational repression of cell cycle
328 inhibitor—CDKN1B and PUM1-CDKN1B regulatory axis may be an important
329 regulatory mechanism in cancer cell proliferation.

330 **Discussion**

331 In this study, we found PUM1 is frequently upregulated in human prostate
332 carcinoma, and downregulation of PUM1 expression reduced PCa cell proliferation and
333 survival. Our data from human cancer cells unveiled a conserved translational
334 regulation of cell cycle regulators by PUM1 in tumorigenesis and prostate cancer
335 progression. Overexpression of *PUM1* contributes to carcinogenesis by repressing the
336 expression of negative cell cycle regulator CDKN1B, unveiling a novel mechanism for
337 the loss of CDKN1B protein expression in tumorigenesis.

338 In cancer, the genetic control of the cell cycle is altered, resulting in unchecked
339 growth and massive cell proliferation. The cell cycle-dependent kinase N1B (CDKN1B)
340 is a negative regulator of the cell cycle and a tumor suppressor. *CDKN1B* is altered in
341 1.85% of all cancers with breast invasive ductal carcinoma, prostate adenocarcinoma,
342 lung adenocarcinoma, colon adenocarcinoma, and testicular mixed germ cell tumor
343 having the greatest prevalence of alterations [24]. Decrease, but not a complete loss of
344 CDKN1B protein activity could stimulate tumorigenesis and is proposed to be an
345 essential step in the development and maintenance of malignant prostatic epithelial cell
346 phenotype [19, 25]. Indeed downregulation of CDKN1B is found in most human prostate
347 cancer [25] and likely in most human tumors [26]. Posttranscriptional regulation of
348 CDKN1B appears to be a primary mechanism for CDKN1B downregulation during
349 tumorigenesis [19, 26],[27], Increased CDKN1B protein degradation via *skp2* *cks1or*
350 protein mislocalization through posttranslational modification were shown to control
351 CDKN1B protein abundance and its tumorigenic function. While RNA binding protein
352 HuD was implicated in reduced expression of CDKN1B in pancreatic cancer [28], but it
353 is not known if translational regulation of CDKN1B abundance level is important for
354 prostate cancer. Our finding that CDKN1B level is regulated at the translational level
355 in prostate cancer cells by PUM1 protein revealed a novel mechanism regulating
356 CDKN1B protein expression in prostate cancer, supporting the important roles of
357 translational control in tumorigenesis.

358 Previously, it was reported the PUM1-mediated E2F3 post-transcription control
359 may be necessary for the growth of cancer cell lines [21], and recently, PUM has been
360 shown to be important for myeloid leukemia cell growth as well as hematopoietic stem

361 cell growth ^[22]. Abnormal expression of PUM proteins was also shown to cause
362 genomic instability ^[29, 30]. However, it was unknown if PUM1 regulates tumorigenesis
363 of solid tumors and to what extent PUM1-CDKN1B regulatory axis is important for
364 cancer cell proliferation and tumor growth. Our findings implicate that PUM1 is a
365 growth regulator in human prostate cancer and potentially a number of other cancers
366 where PUM1 is highly expressed. We identified CDKN1B as the main target of PUM1
367 in a range of prostate cancer cells with features of different aggressiveness and hormone
368 dependency, including both androgen-insensitive and androgen-sensitive cells.
369 Consistent with the downregulation of CDKN1B in prostate cancer and its correlation
370 with poor prognosis ^[31, 32], our findings unveiled a novel regulatory mechanism of
371 CDKN1B downregulation in cancer and a potential target for future therapeutics
372 development.

373 Our previous study indicated PUM1 might regulate other cell cycle targets in mice
374 ^[15, 16]. *PUM1* overexpression in cancer could elicit the growth-promoting effect via
375 repression of targets other than CDKN1B. While other targets of PUM1 in prostate
376 cancer are the subject of the future study, we have found that PUM1-CDKN1b
377 repression appeared to be robust and general among several cell cycle targets in
378 different cancer cells we examined and this axis represented an important regulatory
379 mechanism for cancer cell proliferation. Although the amplification of *PUM1* and
380 *PUM2* locus was detected in a quarter of neuroendocrine prostate cancers ^[33], PUM
381 alleles' gain was not associated with elevated mRNA expression. The mechanism
382 underlying *PUM1* overexpression in prostate cancers is also a subject of future study.

383 It has been reported that 3'UTR of many key regulators of cancers tended to shorten
384 or lost completely during the tumorigenesis ^[34], suggesting that dysregulation in
385 posttranscriptional gene expression may be a common process that contributes to the
386 pathogenesis of neoplasms. Our study of PUM1-mediated translational regulation of
387 cell cycle regulators via binding to their 3'UTR demonstrated an example for such post-
388 transcriptional regulation in cancer and argues for the importance of studying PUM1-
389 CDKN1B regulatory axis in other cancers where the loss of CDKN1B protein
390 expression is associated with tumorigenesis and is a good prognostic marker for cancer

391 survival.

392 Our findings showed that PUM1 is a pro-proliferative factor in normal and
393 neoplastic cells. It contributed to the emerging concept that post-transcription
394 regulation represents a fundamental regulatory mechanism of cell growth. Further
395 studies on the targets of PUM proteins and PUM protein expression regulation are
396 required to fully elucidate their roles during tumorigenesis. The confirmation that
397 PUM1 is essential for cell cycle progression and prostate tumorigenesis supports the
398 potential role of PUM1 as a therapeutic target in PCa. Further examination of the
399 PUM1-CDKN1B regulatory axis in diverse cancers could help understand how broadly
400 this translational control contributes to tumorigenesis.

401 **Acknowledgments**

402 We would like to thank Dr. Yuan Ji at the University of Chicago for advice and
403 discussion on the analysis of TCGA datasets and his lab for assistance. We appreciate
404 comments from Drs. Jindan Yu and Takeshi Kurita as well as anonymous reviewers.
405 This work was supported by the National Science Foundation of China (31771652 and
406 81270737).

407

408 **Reference**

409

410 [1] Wurth L, Gebauer F. RNA-binding proteins, multifaceted translational regulators
411 in cancer[J]. *Biochim Biophys Acta* 2015,1849(7):881-6.

412 [2] Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by
413 HuR[J]. *Wiley Interdiscip Rev RNA (in eng)* 2010,1(2):214-29.

414 [3] Vellky JE, McSweeney ST, Ricke EA, et al. RNA-binding protein DDX3 mediates
415 posttranscriptional regulation of androgen receptor: A mechanism of castration
416 resistance[J]. *Proc Natl Acad Sci U S A* 2020,117(45):28092-28101.

417 [4] Bradner JE, Hnisz D, Young RA. Transcriptional Addiction in Cancer[J]. *Cell*
418 2017,168(4):629-643.

419 [5] Goldstrohm AC, Hall TMT, McKenney KM. Post-transcriptional Regulatory
420 Functions of Mammalian Pumilio Proteins[J]. *Trends Genet* 2018.

- 421 [6] Wickens M, Bernstein DS, Kimble J, et al. A PUF family portrait: 3'UTR
422 regulation as a way of life[J]. *Trends Genet* 2002,18(3):150-7.
- 423 [7] Zamore PD, Williamson JR, Lehmann R. The Pumilio protein binds RNA through
424 a conserved domain that defines a new class of RNA-binding proteins[J]. *RNA*
425 1997,3(12):1421-33.
- 426 [8] Chen D, Zheng W, Lin A, et al. Pumilio 1 suppresses multiple activators of p53 to
427 safeguard spermatogenesis[J]. *Curr Biol (in eng)* 2012,22(5):420-5.
- 428 [9] Gennarino VA, Singh RK, White JJ, et al. Pumilio1 Haploinsufficiency Leads to
429 SCA1-like Neurodegeneration by Increasing Wild-Type Ataxin1 Levels[J]. *Cell*
430 2015,160(6):1087-98.
- 431 [10] Mak W, Fang C, Holden T, et al. An Important Role of Pumilio 1 in Regulating
432 the Development of the Mammalian Female Germline[J]. *Biol Reprod*
433 2016,94(6):134.
- 434 [11] Xu EY, Chang R, Salmon NA, et al. A gene trap mutation of a murine homolog
435 of the Drosophila stem cell factor Pumilio results in smaller testes but does not affect
436 litter size or fertility[J]. *Molecular Reproduction and Development* 2007,74(7):912-
437 921.
- 438 [12] Zhang M, Chen D, Xia J, et al. Post-transcriptional regulation of mouse
439 neurogenesis by Pumilio proteins[J]. *Genes Dev* 2017,31:1354-1369.
- 440 [13] Lin KB, Zhang SK, Chen JL, et al. Generation and functional characterization of
441 a conditional Pumilio2 null allele[J]. *J Biomed Res* 2017,0(0):1-8.
- 442 [14] Gennarino VA, Palmer EE, McDonell LM, et al. A Mild PUM1 Mutation Is
443 Associated with Adult-Onset Ataxia, whereas Haploinsufficiency Causes
444 Developmental Delay and Seizures[J]. *Cell* 2018,172(5):924-936 e11.
- 445 [15] Lin K, Qiang W, Zhu M, et al. Mammalian Pum1 and Pum2 Control Body Size
446 via Translational Regulation of the Cell Cycle Inhibitor Cdkn1b[J]. *Cell Rep*
447 2019,26(9):2434-2450 e6.
- 448 [16] Lin K, Zhang S, Shi Q, et al. Essential requirement of mammalian Pumilio
449 family in embryonic development[J]. *Mol Biol Cell* 2018,29(24):2922-2932.
- 450 [17] Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer:

- 451 prognostic potential and relevance to anticancer therapy[J]. *Nat Rev Cancer*
452 2008,8(4):253-67.
- 453 [18] Kuczyk M, Machtens S, Hradil K, et al. Predictive value of decreased p27Kip1
454 protein expression for the recurrence-free and long-term survival of prostate cancer
455 patients[J]. *Br J Cancer* 1999,81(6):1052-8.
- 456 [19] Polyak K. The p27Kip1 tumor suppressor gene: Still a suspect or proven
457 guilty?[J]. *Cancer Cell* 2006,10(5):352-4.
- 458 [20] Miles WO, Lembo A, Volorio A, et al. Alternative polyadenylation in triple-
459 negative breast tumors allows NRAS and c-JUN to bypass PUMILIO post-
460 transcriptional regulation[J]. *Cancer Res* 2016.
- 461 [21] Miles WO, Tschop K, Herr A, et al. Pumilio facilitates miRNA regulation of the
462 E2F3 oncogene[J]. *Genes Dev (in eng)* 2012,26(4):356-68.
- 463 [22] Naudin C, Hattabi A, Michelet F, et al. PUMILIO/FOXP1 signaling drives
464 expansion of hematopoietic stem/progenitor and leukemia cells[J]. *Blood*
465 2017,129(18):2493-2506.
- 466 [23] Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer
467 transcriptome[J]. *Science* 2017,357(6352).
- 468 [24] Consortium APG. AACR Project GENIE: Powering Precision Medicine through
469 an International Consortium[J]. *Cancer Discov* 2017,7(8):818-831.
- 470 [25] De Marzo AM, Meeker AK, Epstein JI, et al. Prostate stem cell compartments:
471 expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic
472 cells[J]. *Am J Pathol* 1998,153(3):911-9.
- 473 [26] Koff A. How to decrease p27Kip1 levels during tumor development[J]. *Cancer*
474 *Cell* 2006,9(2):75-6.
- 475 [27] Bencivenga D, Caldarelli I, Stampone E, et al. p27(Kip1) and human cancers: A
476 reappraisal of a still enigmatic protein[J]. *Cancer Lett* 2017,403:354-365.
- 477 [28] Kim C, Jeong DE, Heo S, et al. Reduced expression of the RNA-binding protein
478 HuD in pancreatic neuroendocrine tumors correlates with low p27(Kip1) levels and
479 poor prognosis[J]. *J Pathol* 2018,246(2):231-243.
- 480 [29] Lee S, Kopp F, Chang TC, et al. Noncoding RNA NORAD Regulates Genomic

481 Stability by Sequestering PUMILIO Proteins[J]. *Cell* 2016,164(1-2):69-80.

482 [30] Tichon A, Gil N, Lubelsky Y, et al. A conserved abundant cytoplasmic long
483 noncoding RNA modulates repression by Pumilio proteins in human cells[J]. *Nat*
484 *Commun* 2016,7:12209.

485 [31] Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CDKN1B gene is
486 associated with increased risk of hereditary prostate cancer[J]. *Cancer Res*
487 2004,64(6):1997-9.

488 [32] DeMarzo AM, Nelson WG, Isaacs WB, et al. Pathological and molecular aspects
489 of prostate cancer[J]. *Lancet* 2003,361(9361):955-64.

490 [33] Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of
491 castration-resistant neuroendocrine prostate cancer[J]. *Nat Med* 2016,22(3):298-305.

492 [34] Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage
493 and polyadenylation activates oncogenes in cancer cells[J]. *Cell (in eng)*
494 2009,138(4):673-84.

495

496

497

498 **Figure 1. Overexpression of PUM1 is associated with poor prognosis in patients**
499 **with PCa.** (A). Graph showing percentage of patients staining positive for PUM1
500 protein among TCGA cancer types using validated anti-PUM1 antibody from Human
501 Protein Atlas. (B). The box plot comparing *PUM1* expression in the normal prostate
502 gland (Normal) (n=29) and prostate carcinoma (PCa) (n=72) was derived from the
503 Oncomine database (<https://www.oncomine.org/>). (C). The expression of PUM1 in the
504 normal prostate gland and prostate adenocarcinoma specimens. Representative images
505 were taken from the Human Protein Atlas database. (D). The Human Protein Atlas
506 survival analysis for low and high expression levels of PUM1 on 494 prostate cancer
507 patients with death outcome. (E). RT-qPCR examined the expression of PUM1 mRNA
508 in prostate cancer tissue (PCa) and normal prostate tissues (Normal). Human testis
509 (Testis) is a positive control since *PUM1* is highly expressed in the testis. ***P < 0.001.
510 (F). PUM1 protein is increased in prostate cancer cell lines (DU145 and PC3) and tumor
511 tissue from one cancer patient. (G) PUM1 protein level was detected in adjacent normal
512 tissue (N) and prostate carcinoma tissue (PCa) of different cases. (H).
513 Immunohistochemistry of PUM1 protein in prostate carcinoma (PCa) and normal
514 prostate gland (Normal). Scale bar: 200µm (up panel) and 50µm (low panel).

515 **Figure 2. *PUM1* knockdown reduces PCa cell proliferation and survival.** (A). RT-
516 qPCR analysis of *PUM1* mRNA levels as normalized to β -Actin from DU145 cells.
517 Two shRNAs (shPUM1-1 and shPUM1-2) target different *PUM1* transcript and non-
518 targeting shRNA (shCTL) as a control. (B). Immunoblots showing the effect of shRNA-
519 mediated *PUM1* knockdown in DU145 and PC3 cells. (C). CCK8 assay on DU-145
520 cells transfected with the shCTL or with *PUM1* shRNAs as described in (A). ***P <
521 0.001. (D). PC3 cells showed reduced growth after transfected with shRNAs
522 knockdown construct. ***P < 0.001. (E) and (F). Apoptosis assay using flow cytometry
523 after staining with annexin V-FITC/PI. ***P < 0.001, **P < 0.001. (G). Western
524 blotting analysis of apoptosis-related proteins in PC3 and DU145 cells with *PUM1*
525 knockdown. (H). EdU labeling of *PUM1* knockdown DU145 cells revealed
526 significantly reduced proliferation in comparison with control cells. (I). Cell cycle

527 analysis revealed increased G1 and decreased S and G2/M stage cells in *PUM1*
528 Knockdown DU145 cells. **P < 0.01.

529 **Figure 3. Overexpression of *PUM1* promotes prostate cancer cell proliferation and**
530 **colony formation.** (A). Western blot analysis of *PUM1* protein expression from cells
531 overexpressing *PUM1* or *PUM1* and sh*PUM1* at the same time. (B). Cell proliferation
532 assay on *PUM1* overexpression and *PUM1* knockdown. (C). Colony assays were
533 performed on the effect of overexpression of *PUM1* or knockdown of *PUM1* on colony
534 number and size. (D). Colony number was counted for cells containing *PUM1*
535 overexpressing plasmids or knockdown plasmid, or both. *P < 0.05, **p < 0.01.


536 **Figure 4. Knockdown *PUM1* reduces tumorigenesis of DU145 cells in vivo.** (A and
537 B). Representative images of xenografted nude mice (A) and tumors formed from
538 *PUM1* knockdown cells and control cells (B). The black arrowhead indicates *PUM1*
539 knockdown cells, and the red arrow indicates control cells. (C). Tumors from each
540 group of mice were dissected and weighed for comparison of *PUM1* knockdown and
541 shCTL. Histogram showing average tumor weight (N=4) was significantly lower for
542 *PUM1* knockdown cells by comparison with control cells, **P < 0.01. (D). Tumor
543 volumes from each group of mice were measured on the indicated days. **p < 0.01.

544 **Figure 5. *PUM1* represses the translation of *CDKN1B* mRNA by binding to the**
545 **PBE motif on its 3'UTR.** (A). Boxplots showed the expression of *CDKN1B* between
546 normal prostate (n=52) and prostate carcinoma (n=497). Data were obtained from the
547 GEPIA database (<http://gepia.cancer-pku.cn/>). (B). The correlation analysis of *PUM1*
548 and *CDKN1B* in prostate cancer using the GEPIA tool showed that the mRNA
549 expression level of the two genes was correlated to some extent. (C). RT-qPCR analysis
550 of *CDKN1B* mRNA levels in DU145 and PC3 cells with *PUM1* knockdown. (D, E, and
551 F). Western blot analyses of cell cycle proteins expression change from PC3, DU145,
552 and LNCaP cells after 72 hours transfection with sh*PUM1*-1 or shCTL. (G). Western
553 blot analysis of *CDKN1B* protein level from DU145 cells transfected with human
554 *PUM1* (*PUM1*OE) or empty plasmids.

555 **Figure 6. *PUM1* represses *CDKN1B* translation via binding to the 3'UTR of**
556 ***CDKN1B* mRNA.** (A). RNA immunoprecipitation by *PUM1* antibody from DU145


557 and PC3 cell lysates showed PUM1 protein could be specifically pull-down. (B). The
558 RT-qPCR result using PUM1 immune-precipitates versus IgG precipitates showed that
559 *CDKN1B* mRNA was highly enriched from PUM1 IP compared to IgG precipitates.
560 (C). Diagram of wildtype and mutant *CDKN1B* 3'UTR containing two PUF binding
561 elements (PBE) cloned in psiCHECK2 vector. Normalized luciferase activity expressed
562 by the Luc-*CDKN1B* 3'-UTR constructs, co-transfected with the pCMV6-*hPUM1* vs.
563 pCMV6 (Control) in 293T cells. *P < 0.05. (D) Polysome profiles from polysome
564 fractionation experiments of DU145 cells lysate of *PUM1* knockdown (shPUM1) and
565 control. (E) RT-qPCR detected the distribution of *CDKN1B* mRNA in free RNP or
566 polysome fractions. *CDKN1B* mRNAs are significantly increased. *P < 0.05.

567



568

569 Figure 1



570

571 Figure 2

572

573

574

575

576

577

578

579


580

581

582

583

584



585

586 Figure 3

587

588


589

590

591

592


A




B



C



D




593

594 Figure 4


595

596



597
598
599
600
601

Figure 5



602
603
604

Figure 6

605 Supplemental Table I:

<i>hPUM1</i>	Forward:(5'-3') TGAATCCAGCAAAGATGGACC
	Reverse:(5'-3') A TACTCCACCATGCTAACGCC
<i>hCDKN1B</i>	Forward:(5'-3') AACGTGCGAGTGTCTAACGG
	Reverse:(5'-3') CCCTCTAGGGGTTTGTGATTCT
<i>hβ-ACTIN</i>	Forward:(5'-3') CATGTACGTTGCTATCCAGGC
	Reverse:(5'-3') CTCCTTAATGTCACGCACGAT

606

Supplemental Table II. Clinical demographics of the prostate cancer cohort (n=20)

Number of patients	20
Age (y)	
Mean ± SD	70.5 ± 4.59
Median	68
Range	61 - 76
Preoperative PSA (ng/ml)	
Mean ± SD	12.33 ± 5.42
Median	11.9
Range	5.7 – 24.5
Pathological data	
Stage	
pT2	15
pT3	9
Gleason score	
7	16
>7	4

607